about
sameAs
Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s DiseaseOptimization of the All-D Peptide D3 for Aβ Oligomer EliminationCompetitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and ToxicityQIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomersCorrection: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity.Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.Structure characterization of unexpected covalent O-sulfonation and ion-pairing on an extremely hydrophilic peptide with CE-MS and FT-ICR-MS.The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma.Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.Combining independent drug classes into superior, synergistically acting hybrid molecules.Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
P50
Q27305174-0D032F74-8DA1-48AF-98FC-DA6EAF4DC591Q28275093-F69C87DD-3707-46CC-AAC3-B1B79DF56594Q28601353-453700F6-715F-47E7-AA50-0C0EE2AB4F2DQ36099501-94DDD60A-8AB0-4C77-953D-6D623651081DQ42424949-42709C52-85A0-44F7-81B5-89332717E563Q46244365-4218F954-1946-400F-94C1-101C14360269Q46540524-1DDA8DAD-2184-498B-BF0F-86BEFB3A076FQ46707622-9A55AEB9-6334-4EA5-B1DB-FA1483379C85Q47144123-8FE8F3B9-0060-43DC-B8D0-45543724DA3CQ47223345-732F156F-AE76-413B-A8CB-129E57AC65A5Q47242757-BCC84643-2036-4606-A306-1E569A631270Q47672693-7D2DE1EE-719C-4118-B7FE-D177C81907E1Q47920093-B3A96A15-089B-4CB3-BD11-3E4CBB59AD43Q48327869-AEC65EEC-A8AA-4B11-B0D4-D3A78B925DC5Q51771510-24951534-D576-4D1A-9841-B19D7761DDE2Q52139607-D4A8AAAD-E00A-45D7-BF8E-ADC2A2A3BC6BQ52149113-5A5CDBB9-D8FD-4BB4-BD9D-6EDB8C503350
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Janine Kutzsche
@ast
Janine Kutzsche
@en
Janine Kutzsche
@es
Janine Kutzsche
@nl
Janine Kutzsche
@sl
type
label
Janine Kutzsche
@ast
Janine Kutzsche
@en
Janine Kutzsche
@es
Janine Kutzsche
@nl
Janine Kutzsche
@sl
prefLabel
Janine Kutzsche
@ast
Janine Kutzsche
@en
Janine Kutzsche
@es
Janine Kutzsche
@nl
Janine Kutzsche
@sl
P1053
G-6287-2013
P106
P21
P31
P3829
P496
0000-0003-0271-7390